Citokine-induced thyroid disorders

Cover Page

Abstract


Review of the literature devoted to the actual problem that has been raised in connection with the widespread use of preparations of interferon in the treatment of various diseases. It is obvious that the thyroid function disorders often develop as the result of interferon therapy. This review presents the recent data on prevalence, clinical presentation and course, as well as the principles of treatment of interferon-induced thyroid disorders.

About the authors

Email: walfad@mail.ru

References

  1. Абдрашитов Р.Ф. Диагностическая и прогностическая ценность неинвазивных методов определения степени фиброза у больных ХВГ: Автореф. дис.. канд. мед. наук. Томск, 2006.
  2. Апросина З.Г., Серов В.В. Хронические вирусные заболевания печени: пато- и морфогенез, клиническая характеристика // Тер. архив. 1995. Т. 67. №5. С. 77–79.
  3. Апросина З.Г. Последние достижения в изучении вирусных гепатитов // Рус. мед. журн. 1996. Т. 4. №3. С. 174-176.
  4. Бикбавова Г.Р. Провоспалительные и противовоспалительные цитокины в формировании клинической картины хронического вирусного гепатита В, хронического описторхоза и их сочетаний: Автореф. дис.. канд. мед. наук. Омск, 2005.
  5. Вечеринина О.О. Влияние жирового гепатоза и синдрома инсулинрезистентности на эффективность противовирусной терапии ХГС // Автореф. дис.. канд. мед. наук. М., 2007.
  6. Дедов И.И. Болезни органов эндокринной системы. М.: Медицина, 2000.
  7. Журавлева З.В. Клинико-лабораторное обоснование диагностики парентеральных вирусных гепатитов В и С по стоматологическому статусу // Автореф. дис.. канд. мед. наук. Тверь, 2006.
  8. Ивашкин В.Т., Маевская М.В. Современные принципы ведения пациентов с хронической инфекцией вирусом гепатита В: клиническое значение уровня вирусной нагрузки // Клин. персп. гастроэнтерол., гепатол. 2006. №5. С. 17–24.
  9. Калинин Ю.Т., Воробьев А.А., Бумялис В.В. и др. Итоги клинических испытаний и перспективы применения в медицинской практике рекобинантного интеррферона альфа-2В // Журн. микробиол. 1990. №9. С. 61-67.
  10. Корочкина О., Соболевская О. Особенности гепатита А на современном этапе // Врач. 2006. №7. С. 17–19.
  11. Навроцкий А.Н. Диагностика и клинико-лабораторная характеристика острых вирусных гепатитов у работников медицинских профессий: Докл. на Юбил. научн.-практ. конф., посв. 75-летию кафедр инфекц. бол. взрослых и детей ОмГМА “Актуальные вопросы инфекционной патологии”. Омск, 2005. С. 20–21.
  12. Наследникова Н.О. Иммунорегуляторные цитокины и хронизация вирусного гепатита С: клинико-иммунологические параллели // Клин. мед. 2005. Вып. 83. №9. С. 40–44.
  13. Раков А.Л., Горбаков В.В. Неалкогольный стеатогепатит // Воен.-мед. журн. 2006. Т. 327. №7. С. 33–39.
  14. Скляр Л.Ф., Никифорова Н.Д., Маркелова Е.В. Цитокиновый профиль при хроническом гепатите С // Клин. мед. 2005. Вып. 83. №10. С. 40–44.
  15. Степанова Т.В., Тордия Н.Л., Абдуллаева Х.И. Эффективность комбинированной терапии у больных хроническим гепатитом С с нормальной и повышенной эхогенностью печени // Матер. X Рос. конф. “Гематология сегодня”, 28–30 марта 2005 г. // Рос. журн. гастроэнтерол., гепатол., колоп- роктол. 2005. Т. 15. №1 (Приложение №24). С. 7.
  16. Фадеев В.В., Мельниченко Г.А. Гипотиреоз: Руководство для врачей. М., 2002.
  17. Чупрунова С.В. Клинико-иммунологические особенности токсикоза вирусного гепатита В средней степени тяжести на фоне лечения человеческим лейкоцитарным интерфероном: Автореф. дис.. канд. мед. наук. Ярославль, 1990.
  18. Эттингер О.А. Хронический гепатит С: состояние тиреоидного статуса на фоне лечения интерфероном-α: Автореф. дис.. канд. мед. наук. М., 2000.
  19. Ягода А.В., Гейвандова Н.И., Корой П.В. Способ прогнозирования результатов лечения больных хроническим вирусным гепатитом C препаратами интерферона-α: Пат. 2287825. МКИ7 GO1N 33/68. // Ставр. гос. мед. акад. №2005123600/15. Заявл. 25.07.05. Опубл. 20.11.06.
  20. Akpolat N., Yahsi S., Godekmerdan A. et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B // Wld. J. Gastroenterol. 2005. V. 11(21). P. 3260–3263.
  21. Akyuz F., Polat N., Kaymakogiu S. et al. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus- infected patients with persistently normal and elevated amino- transferase levels // Wld. J. Gastroenterol. 2005. V. 11. N5. P. 7188–7191.
  22. Amenomori M., Mori T., Fukuda Y. et al. Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C // Intern. Med. 1998. V. 37(3). P. 246–252.
  23. Baron S., Tyring S.K., Fleischmann Jr.W.R. et al. The interferons. Mechanisms of action and clinical applications // J.A.M.A. 1991. V. 266 (10). P. 1375–1383.
  24. Beckman D.B., Mathisen T.L., Harris K.E. et al. Hypersensitivity to IFN-alpha // Allergy. 2001. V. 56. N8. P. 806–807.
  25. Bini E.J., Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study // Arch. Intern. Med. 2004. V. 164(21). P. 2371–2376.
  26. Bonifazi F. Bonifazi F., de Vivo A., Rosti G. et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders // Blood. 2001. V. 98. N10. P. 3074–3081.
  27. Carella C., Mazziotti G., Morisco F. et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treat- ment // J. Clin. Endocrinol. Metab. 2001. V. 86(5). P. 1925–1929.
  28. Carella C., Mazziotti G., Amato G. et al. Interferon-α-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects // J. Clin. Endocrinol. Met. 2004. V. 89. N8. P. 3656–3661.
  29. Ciampolillo A., Guastamacchia E., Amati L. et al. Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration // Cur. Pharm. Des. 2003. N9. P. 1946–1950.
  30. Dalgard O., Bjoro K., Hellum K. et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon α no association with either interferon dosage or efficacy of therapy // J. Intern. Med. 2002. V. 251. P. 400–406.
  31. Deutsch M., Dourakis S., Manesis E.K. et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy // Hepa-tol. 1997. V. 26. P. 206.
  32. di Cesare E., Previti M., Russo F. et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis // Dig. Dis. Sci. 1996. V. 41 (8). P. 1672–1677.
  33. Doi F., Kakizaki S., Takagi H. et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C // Liver Int. 2005. V. 25(2). P. 242–246.
  34. Durelli L., Ferrero B., Oggero A. et al. Thyroid function and autoimmunity during interferon-1b treatment: a multicenter prospective study // J. Clin. En-docrinol. Metab. 2001. V. 86 (8). P. 3525–3532.
  35. Eugéne C., Tennenbaum R., Anciaux M.L. et al. Autoimmune dysthyroidism induced by alpha interferon in two female patients with chronic non-A, non-B hepatitis // Gastroenterol. Clin. Biol. 1993. V. 17 (8–9). P. 594–597.
  36. Fernandez(Soto L., Gonzales A., Escobar(Jimenez F. et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon ther- apy // Arch. Intern. Med. 1998. V. 158. P. 1445–1448.
  37. Gowans E.J. Distribution of markers of hepatitis C virus infection throughout the body // Semin. Liver. Dis. 2000. V. 20(1). P. 85–102.
  38. Gutierrez G., Pereda A. Granulocyte colony stimulating factor for the treatment of interferon-induced neutropenia in patients with chron- ic hepatitis // J. Pediatr Gastroenterol Nutr. 2001. V. 32. N2. P. 225.
  39. Hsieh M.C., Yu M.L., Chuang W.L. et al. Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C // Eur. J. Endocrin. 2000. V. 142. P. 431-437.
  40. Huang M.J., Liaw Y.F. Clinical associations between thyroid and liver diseases // J. Gastroenterol. Hepatol. 1995. V. 10 (3). P. 344–350.
  41. Imagawa A., Itoh N., Handfusa T. et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepa-titis // J. Сlin. Endocrin. Met. 1995. V. 80. N3. P. 922–926.
  42. Irving W.J., Smith S., Cater R. et al. Clinical pathways for patients with newly diagnosed hepatitis C – what actually happens // J. Viral Hepatitis. 2006. V. 13. N4. P. 264–271.
  43. Jacobs E.L., Clare(Salzler M.J., Chopra I.J., Figlin R.A Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-α // J. Immunother. 1991. N10. P. 448–455.
  44. Kabbaj N., Guedira M.M., El Atmani H. et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study // Ann. Endocrin. 2006. V. 67. P. 343.
  45. Kalaycio M.E. Chronic myelogenous leukemia: the news you have and haven't heard // Cleve Clin. J. Med. 2001. V. 68. N11. P. 913, 917, 920–921, 925–956.
  46. Koh L.K.H., Greenspan F.S., Yeo P.P.B. Interferon-α induced thyroid dysfunction: three clinical presentations and review of the literature // Thyroid. 1997. V. 7. P. 891–896
  47. Lisker(Melman M., Di Bisceglie A.M., Usala S.J. et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa // Gastroenterol. 1992. V. 102. P. 2155–2160.
  48. Lloyd A.R., Jagger E., Post J.J. et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection // Immunol. Cel. Biol. 2007. V. 85. P. 24–32.
  49. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification // Hepatol. 2006. V. 43. P. 661.
  50. Marazuela M., Garcia(Buey L., Gonzalez(Fernandez B. et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy// Clin. Endocrinol. 1996. V. 44. P. 635–642.
  51. Martin J., Navas S., Quiroga J.A. et al. Effects of the ribavirin-interferon-α combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients // Cytokine. 1998. N10. P. 635–644.
  52. Matsuda J., Saitoh N., Gotoh M. et al. High prevalence of antiphospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon- alpha // Am. J. Gastroenterol. 1995. V. 90(7). P. 1138–1141.
  53. Mazziotti G., Sorvillo F., Naclerio C. et al. Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis // Eur. J. Endocrin. 2003. V. 148. P. 383–388.
  54. Nagayama Y., Ohta K., Tsuruta M. et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature // Endocrin. J. 1994. V. 41. P. 565–572.
  55. Poupon R., Serfaty L. Prevention and treatment of hepatitis C // Bull. Acad. Nat. Med. 1996. V. 180. N6. P. 1279–1289.
  56. Preziati D., La Rosa L., Covini G. et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a // Eur. J. Endocrin. 1995. V. 132 (5). P. 587–593.
  57. Prummel M.F., Laurberg P. Interferon-alpha and autoimmune thyroid disease // Thyroid. 2003. V. 13(6). P. 547–551.
  58. Rönnblom L.E., Alm G.V., Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment // Acta Oncol. 1991. V. 30 (4). P. 537–540.
  59. Ridgway E.C., Tomer Y., McLachlan S.M. Update in thyroidology // J. Clin. Endocrinol. Met. 2007. V. 92(10). P. 3755–3761.
  60. Roti E., Minelli R., Giuberti T. et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha // Am. J. Med. 1996. V. 101. P. 482–487.
  61. Sacchi S., Kantarjian H., O'Brien S. et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia // J. Clin. Oncol. 1995. V. 13. P. 2401.
  62. Spiegel M., Weber F., Kochs G. International Symposium Threat of Infection: Microbes of High Pathogenic Potential-Strategies for Detection, Control and Eradication, 25–28 July, 2004. Würzburg // Nova Acta Leopoklina. 2005. V. 92. N344. P. 189–197.
  63. Terpos E., Terpos E., Palermos J., Viniou N. et al. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-α treatment // Calcif Tis. Int. 2001. V. 68. N5. P. 285–290.
  64. Tomer Y., Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link? //Am. J. Med. 2004. V. 117. P. 60–66.
  65. Tong M.J., Reddy K.R., Lee W.M. et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group // Hepatol. 1997. V. 26. P. 747.
  66. Tran A., Quaranta J.F., Benzaken S. et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy // Hepatol. 1993. V. 18 (2). P. 253–257.
  67. Tran H.A., Reeves G.E. The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-α Therapy for Chronic Hepatitis C // Int. J. Endocrinol. 2009; ID 241786
  68. Vial T., Descotes J. Immunemediated side-effects of cytokines in humans // Toxicol. 1995. V. 105 (1). P. 31–57.
  69. Vial T., Choquet-Kastylevsky G., Liautard C., Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons // Toxicol. 2000. V. 142 (3). P. 161–172.
  70. Zorzitto J., Galligan C.L., Ueng J., Fish E.N. Characterization of the antiviral effects of interferon-α against a SARS-like coronavirus infection in vitro // Cel. Res. 2006. V. 16. N2. P. 220–229.

Statistics

Views

Abstract - 983

PDF (Russian) - 617

Cited-By


PlumX

Dimensions


Copyright (c) 2011 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies